Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development

  • Caladrius Biosciences Inc CLBS has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.
  • The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.
  • Cassava Sciences Inc SAVA has been awarded a new $2.7 million research grant award from the National Institutes of Health.
  • The grant will be used to fund its upcoming Phase 3 program with simufilam, its drug candidate for Alzheimer's disease.
  • Price Action: CLBS shares are trading 0.68% lower at $1.45, and SAVA shares are down 2.73% at $38.16 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFinancingSmall CapGeneralAlzheimer's diseaseBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!